Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial
The Lancet regional health. Western Pacific（2023）
Key words
SARS-CoV-2,Adenovirus type 5-vectored vaccine,Inactivated vaccine,Heterologous immunisation,Elderly
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined